Indication
Stage III Major Salivary Gland Cancer AJCC v8
3 clinical trials
3 products
4 drugs
Clinical trial
Phase I Trial of BAY 1895344 ATR Inhibitor Combined With Stereotactic Body Radiation Therapy and Pembrolizumab for Recurrent Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-11-27
Product
ElimusertibDrug
mFOLFOX6Clinical trial
Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)Status: Recruiting, Estimated PCD: 2026-03-31
Drug
CeralasertibProduct
Trastuzumab DeruxtecanClinical trial
A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naive, Unresectable HER2-Positive Salivary Gland CancerStatus: Recruiting, Estimated PCD: 2028-07-31
Drug
DocetaxelDrug
TrastuzumabProduct
Trastuzumab Emtansine